ArticleThoracic cancer2026
Addition of Immune Checkpoint Inhibitor to Platinum Retreatment for Recurrent Non-Small Cell Lung Cancer After Perioperative Chemotherapy: A Multicenter Retrospective Study.
Article in Thoracic cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe addition of immune checkpoint inhibitor (ICI) to platinum-based chemotherapy has improved outcomes in patients with advanced non-small cell lung cancer (NSCLC). However, evidence on the efficacy of adding ICI to platinum retreatment in patients who relapse after perioperative platinum-based chemotherapy remains limited.
methodsWe retrospectively analyzed patients with recurrent NSCLC following perioperative platinum-based chemotherapy. Patients were categorized into either the "chemo group," who received platinum retreatment without ICI, or the "ICI-chemo group," who received platinum retreatment with ICI. The primary endpoint was progression-free survival in patients treated with ICI.
resultsAmong 124 patients who received perioperative platinum therapy and surgery, 31 underwent platinum retreatment: 17 in the chemo group and 14 in the ICI-chemo group. PFS was significantly longer in the ICI-chemo group than in the chemo group (15.4 vs. 5.9 months; log-rank p = 0.023; HR 0.40, 95% CI, 0.18-0.90). Among patients with PD-L1 ≥ 50%, the ICI-chemo group showed a greater trend toward longer PFS compared with the chemo group (16.9 vs. 4.0 months; HR 0.11, 95% CI, 0.01-1.05).
conclusionsAdding ICI to platinum retreatment may be an effective option for patients with NSCLC who relapse after perioperative chemotherapy, particularly in those with PD-L1 expression ≥ 50%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.